Table 5 Secondary Analysis: The addition of hs-CRP into longitudinal models of respiratory outcomes did not substantively change the predictive relationship between MMP-9 and the outcomes examined.
From: Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency
Outcome Measures | MMP-9 Annualized Δ* (95% CI) p-value | hs-CRP Annualized Δ* (95% CI) p-value |
|---|---|---|
Spirometry | ||
FEV1, ml | +15 (-4 to +34) p = 0.12 | -25 (-73 to +22) p = 0.29 |
FVC, ml | +72 (+6 to +139) p = 0.03 | -28 (-192 to +136) p = 0.73 |
FEV1/FVC ratio | -0.6%(-1.3% to +0.01%) p = 0.053 | -1.3%(-2.9% to +0.3%) p = 0.11 |
Total Lung Capacity, ml | +69 (+10 to +127) p = 0.02 | +17 (-156 to +190) p = 0.85 |
Transfer Factor (TLco), mmol/min/kpa | -0.1 (-0.2 to -0.002) p = 0.047 | -0.07 (-0.4 to -0.2) p = 0.63 |
CT Densitometry | ||
Adjusted Lung Density† | -0.6 (-1.0 to -0.2) p = 0.006 | +0.7 (-0.3 to +1.7) p = 0.16 |
Resting Oxygenation Saturation (room air) | -0.4%(-0.6% to -0.2%) p < 0.001 | -0.9% (-1.4 to -0.4) p = 0.001 |
Incremental Shuttle Walk Test Distance, meters | -6 (-14 to +3) p = 0.20 | -20 (-42 to +1) p = 0.07 |
Acute Exacerbations of COPD, number | +0.26 (+0.08 to +0.45) p = 0.006 | +0.16 (-0.6 to +0.9) p = 0.67 |